Zhang T, Yu X, Yang X, Li Y, Li X, Ma L
Ther Clin Risk Manag. 2025; 21:283-292.
PMID: 40066058
PMC: 11892500.
DOI: 10.2147/TCRM.S508507.
Wang F, Wang Y, Xiong B, Yang Z, Wang J, Yao Y
Signal Transduct Target Ther. 2025; 10(1):45.
PMID: 39875376
PMC: 11775149.
DOI: 10.1038/s41392-025-02138-6.
Niu S, Sun T, Wang M, Yao L, He T, Wang Y
BMC Cancer. 2025; 25(1):115.
PMID: 39844103
PMC: 11752932.
DOI: 10.1186/s12885-025-13526-0.
Nezhad N, Nezhad H, Shahpar A, Shahrebabak A, Shahrebabak M, Farokhi F
BMC Infect Dis. 2024; 24(1):1369.
PMID: 39614184
PMC: 11607866.
DOI: 10.1186/s12879-024-10270-x.
Khan A, Ahuja S, G K, Zaheer S
Indian J Surg Oncol. 2024; 15(4):802-808.
PMID: 39555334
PMC: 11564480.
DOI: 10.1007/s13193-024-02001-0.
Peripheral NK cell count predicts response and prognosis in breast cancer patients underwent neoadjuvant chemotherapy.
Zhang C, Wu F, Lu X, Wang S, Wu M, Chen N
Front Immunol. 2024; 15:1437193.
PMID: 39403373
PMC: 11471483.
DOI: 10.3389/fimmu.2024.1437193.
Locoregional recurrence in studies of primary systemic therapy in early invasive breast cancer.
Chen L, McIntosh S, Tyagi S, Dodwell D
Breast. 2024; 77:103791.
PMID: 39217831
PMC: 11402831.
DOI: 10.1016/j.breast.2024.103791.
Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response in triple-negative breast cancer: A systematic review and meta-analysis.
Sun H, Jiang W, Zhang S, Xu P, Wei L, Liu J
World J Clin Oncol. 2024; 15(7):920-935.
PMID: 39071463
PMC: 11271722.
DOI: 10.5306/wjco.v15.i7.920.
Quality of life in women with breast cancer undergoing neoadjuvant chemotherapy: comparison between PICC and PICC-port.
Pinelli F, Barbani F, Defilippo B, Fundaro A, Nella A, Selmi V
Breast Cancer. 2024; 31(5):945-954.
PMID: 38980572
PMC: 11341727.
DOI: 10.1007/s12282-024-01608-z.
Promoter profiles in plasma CfDNA exhibits a potential utility of predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients.
Yang X, Liu Q, Guo Z, Yang X, Li K, Han B
Breast Cancer Res. 2024; 26(1):112.
PMID: 38965610
PMC: 11225256.
DOI: 10.1186/s13058-024-01860-3.
Neoadjuvant Chemotherapy Is Effective in Those Infected With SARS-CoV-2: The Real-World Experience of a Large Chinese Breast Cancer Center.
Ma T, Ma T, Wang L, Wang H
J Breast Cancer. 2024; 27(3):176-186.
PMID: 38769687
PMC: 11221209.
DOI: 10.4048/jbc.2023.0299.
Image quality evaluation for a clinical organ-targeted PET camera.
Baldassi B, Poladyan H, Shahi A, Maa-Hacquoil H, Rapley M, Komarov B
Front Oncol. 2024; 14:1268991.
PMID: 38590664
PMC: 10999605.
DOI: 10.3389/fonc.2024.1268991.
Predictive value of background parenchymal enhancement on breast magnetic resonance imaging for pathological tumor response to neoadjuvant chemotherapy in breast cancers: a systematic review.
Li X, Yan F
Cancer Imaging. 2024; 24(1):35.
PMID: 38462607
PMC: 10926651.
DOI: 10.1186/s40644-024-00672-0.
The MARECA (national study of management of breast cancer locoregional recurrence and oncological outcomes) study: protocol for a prospective, multicentre cohort study.
Hartup S, Morgan J, Cheng V, Barry P, Copson E, Cutress R
Int J Surg Protoc. 2024; 28(1):20-26.
PMID: 38433867
PMC: 10905491.
DOI: 10.1097/SP9.0000000000000018.
Impact of oncoplasty in increasing breast conservation rates Post neo-adjuvant chemotherapy.
Koppiker C, Kelkar D, Kulkarni M, Kadu S, Pai M, Dhar U
Front Oncol. 2023; 13:1176609.
PMID: 37746279
PMC: 10514208.
DOI: 10.3389/fonc.2023.1176609.
Oncoplastic and reconstructive breast surgery.
Wignarajah P, Malata C, Benson J
Front Oncol. 2023; 13:1176915.
PMID: 37448512
PMC: 10338173.
DOI: 10.3389/fonc.2023.1176915.
Real‑world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high‑risk breast cancer subgroup patients.
Li Z, Li Y, Liu Y, Shang Y, Zhou Y, Ji X
Oncol Lett. 2023; 25(5):193.
PMID: 37113400
PMC: 10126659.
DOI: 10.3892/ol.2023.13779.
The innovative model based on artificial intelligence algorithms to predict recurrence risk of patients with postoperative breast cancer.
Zeng L, Liu L, Chen D, Lu H, Xue Y, Bi H
Front Oncol. 2023; 13:1117420.
PMID: 36959794
PMC: 10029918.
DOI: 10.3389/fonc.2023.1117420.
Comprehensive evaluation of breast cancer immunotherapy and tumor microenvironment characterization based on interleukin genes-related risk model.
Lv Y, Bai Z, Wang X, Liu J, Li Y, Zhang X
Sci Rep. 2022; 12(1):20524.
PMID: 36443508
PMC: 9705306.
DOI: 10.1038/s41598-022-25059-8.
The neoadjuvant chemotherapy responses and survival rates of patients with different molecular subtypes of breast cancer.
Zhang H, Zhang X, Jin L, Wang Z
Am J Transl Res. 2022; 14(7):4648-4656.
PMID: 35958459
PMC: 9360845.
